Overall verdict
Sell
2.6/10
1-year performance
-63.41%
Score breakdown
Down 63.4% over 1 year, 7% of the 52-week range.
Strongest: Financial strength 5.8/10. Weakest: Shareholder return 0.0/10.
12 analysts, target +2.1% vs the price.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nyse
United States
CEO
Luis Pena
Founded
2020
Employees
48
Revenue / employee
270 833 USD
Next earnings
March 5, 2027 (estimated)
Institutional holders
- BlackRock, Inc.2.79%
- GEODE CAPITAL MANAGEMENT, LLC1.13%
- GOLDMAN SACHS GROUP INC0.73%
- STATE STREET CORP0.65%
- FMR LLC0.41%
- MORGAN STANLEY0.23%
- JPMORGAN CHASE & CO0.10%
- Bank of New York Mellon Corp0.07%
- Rest of the register93.90%
8 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
33.20 USD
52-week low
4.94 USD
1-year performance
-63.41%
Declining
Year-to-date performance
-59.35%
Declining
Drawdown
-78.80%
Major drawdown
Position in the 52-week range
7% of range
ROIC -68.1%, ROE -331.4%.
Net margin
—
Sector -213.59%|S&P 13.35%
Gross margin
—
Return on equity (ROE)
-331.43%
Negative
Sector -55.30%|S&P 16.98%
Return on invested capital (ROIC)
-68.13%
Negative
Free cash flow margin (FCF)
—
Revenue to net income
Growth
0.0/10Revenue down 100.0% over 1 year.
Revenue (trailing 12 months)
0 USD
Revenue growth (1y)
-100.00%
Declining
Revenue growth (3y)
—
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.0x|S&P 22.1x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
—
N/A (loss)
Sector 16.5x|S&P 14.9x
PEG
—
Sector 0.87|S&P 0.84
Market cap
291M USD
Financial strength
5.8/10Cash covers 2058.6% of the debt, no net debt (net cash).
Net debt / EBITDA
—
Gearing (net debt / equity)
-63.83%
Net cash
Cash
169M USD
Cash / market cap
57.93%
Very solid
Cash / total debt
2058.57%
Net cash
Interest coverage
-11581.6x
Stretched
Net debt
-160M USD
Equity
251M USD
Closed daily candles, 12 months
Last close on November 20, 2026: 7.04 USD
- MM206.81
- MM507.13
- MM20016.87
- RSI 1450.1
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-7.17%
50-day average slope, 1 month
-27.28%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
7.58 % per day
Volatility change
+36.56%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -3.32 (8) | -3.28 (10) | 1 (9) | -142 (1) | -120 (8) |
| 2027 | -3.59 (10) | -3.42 (12) | 1 (9) | -144 (2) | -151 (9) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 16, 2026.
Same sub-industry: 797 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ALERS | 4.5 | 4.5 | 284M USD | 36.9x | 4.2 % | 9.1 % | 3.7 % | -0.1x | 2.0 % | 8.2 % | ||
| 2 | BNTC | 4.0 | N/A | 286M USD | Not meaningful (loss) | — | — | -37.5 % | 3.2x | -6.2 % | -40.5 % | ||
| 3 | SPRY | 2.7 | 3.0 | 298M USD | Not meaningful (loss) | -163.6 % | 16.0 % | -112.7 % | 0.1x | -61.5 % | -59.0 % | ||
| 4 | 7630 | 2.7 | 2.7 | 292M USD | Not meaningful (loss) | -213.6 % | 14.1 % | -60.5 % | 5.4x | -4.8 % | -77.2 % | ||
| 5 | EVMN | 2.6 | 0.9 | 291M USD | Not meaningful (loss) | — | -100.0 % | -68.1 % | — | -31.3 % | -63.4 % | ||
| 6 | 4894 | 2.1 | 1.5 | 296M USD | Not meaningful (loss) | -1478.4 % | -52.6 % | -15.8 % | 5.0x | — | -13.8 % | ||
| 7 | 6945 | 1.5 | N/A | 287M USD | Not meaningful (loss) | — | — | -22.4 % | 4.5x | -4.1 % | -7.9 % | ||
| 8 | GLSI | 1.5 | N/A | 283M USD | Not meaningful (loss) | — | — | -10656.2 % | 0.3x | -4.5 % | 134.2 % | ||
| 9 | 2617 | 1.5 | N/A | 294M USD | Not meaningful (loss) | -738.1 % | — | -36.0 % | 3.6x | -12.3 % | -96.8 % |
